05:17 AM EDT, 06/21/2024 (MT Newswires) -- Bausch Health Companies ( BHC ) and its Salix Pharmaceuticals gastroenterology business said Thursday they have filed a patent infringement lawsuit against Alvogen subsidiary Norwich Pharmaceuticals over its attempt to market a generic version of Salix's diarrhea-predominant irritable bowel syndrome treatment Xifaxan..

The lawsuit filed in the US District Court for the District of New Jersey is in connection with Norwich's amendment to an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market a generic version of the drug, also known as rifaximin.

Basuch said the US District Court for the District of Delaware in 2022 issued a ruling that barred Norwich's first Abbreviated New Drug Application for a generic version of the drug until October 2029.

Norwich's parent company Alvogen did not immediately reply to MT Newswires' request for comment.

Price: 6.75, Change: +0.02, Percent Change: +0.30